Christopher Rhodes to Glucagon-Like Peptide-1 Receptor
This is a "connection" page, showing publications Christopher Rhodes has written about Glucagon-Like Peptide-1 Receptor.
Connection Strength
1.560
-
GLP-1R/GCGR dual agonism dissipates hepatic steatosis to restore insulin sensitivity and rescue pancreatic ß-cell function in obese male mice. Nat Commun. 2025 May 21; 16(1):4714.
Score: 0.907
-
Specific loss of GIPR signaling in GABAergic neurons enhances GLP-1R agonist-induced body weight loss. Mol Metab. 2025 May; 95:102074.
Score: 0.219
-
Combined loss of GLP-1R and Y2R does not alter progression of high-fat diet-induced obesity or response to RYGB surgery in mice. Mol Metab. 2019 07; 25:64-72.
Score: 0.149
-
Pancreatic ß-Cell Rest Replenishes Insulin Secretory Capacity and Attenuates Diabetes in an Extreme Model of Obese Type 2 Diabetes. Diabetes. 2019 01; 68(1):131-140.
Score: 0.143
-
Peptide-YY3-36/glucagon-like peptide-1 combination treatment of obese diabetic mice improves insulin sensitivity associated with recovered pancreatic ß-cell function and synergistic activation of discrete hypothalamic and brainstem neuronal circuitries. Mol Metab. 2022 01; 55:101392.
Score: 0.044
-
A genetic map of the mouse dorsal vagal complex and its role in obesity. Nat Metab. 2021 04; 3(4):530-545.
Score: 0.042
-
Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis. Nat Metab. 2020 05; 2(5):413-431.
Score: 0.040
-
Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B. Diabetologia. 2005 Jul; 48(7):1339-49.
Score: 0.014